1-5 of 5
Kevin Kwei
Close
Sort by
Journal Articles

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Jan A. Burger, MD PhD, Tadeusz Robak, MDPhD, Fatih Demirkan, MD, Osnat Bairey, MD, Carol Moreno, MD PhD, David Simpson, MBChB, FRACP, FRCPA, Talha Munir, MBBS, Don A. Stevens, MD, Sandra Dai, PhD MS, Leo W. K. Cheung, PhD, Kevin Kwei, PhD, Indu Lal, MD, Emily Hsu, PhD, Thomas J. Kipps, MD PhD, Alessandra Tedeschi, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-134437
Published: 2020
Journal Articles

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib

Adrian Wiestner, MD PhD, Paolo Ghia, MD PhD, John C. Byrd, MD, Inhye E Ahn, MD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Daniel Jones, MD PhD, Leo W. K. Cheung, PhD, Elizabeth Chong, PhD, Kevin Kwei, PhD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Jennifer A. Woyach, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
https://doi.org/10.1182/blood-2020-134386
Published: 2020
Journal Articles

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Radhakrishnan Ramchandren, MD, Peter Johnson, MDFRCP, Nilanjan Ghosh, MD PhD, Jia Ruan, MD PhD, Kirit M. Ardeshna, MA, MD FRCP, FRCPath, Roderick Johnson, MD, Gregor Verhoef, MD PhD, David Cunningham, MD FRCP, FMedSci, Sven de Vos, MD PhD, Shireen Kassam, MD, Luis Fayad, MD, John Radford, Sarah Bailly, MD, Fritz Offner, MD, David Morgan, MD, Javier Munoz, MD, Jerry Ping, PhD, Kevin Kwei, PhD, Karl Eckert, BA, Jutta K. Neuenburg, MD PhD, Andre Goy, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 761.
https://doi.org/10.1182/blood-2019-121521
Published: 2019
Journal Articles

Ibrutinib Therapy in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Analysis By Prior Rituximab Treatment and Baseline Mutations

Robert Chen, MD, Sven de Vos, MD PhD, Catherine Thieblemont, MD PhD, Peter Martin, FRCPC, MD MS, Christopher Flowers, MD, Franck Morschhauser, MD PhD, Graham Collins, MD PhD, Shuo Ma, MD, Morton Coleman, MD, Shachar Peles, MD, Stephen D. Smith, MD, Jacqueline C. Barrientos, MD, Alina Smith, Brian Munneke, PhD, Shiquan Wu, PhD, Leo Cheung, PhD, Kevin Kwei, PhD, Selda Samakoglu, MD PhD, Israel Arango-Hisijara, MD, Isaiah Dimery, MD, Ariela Noy, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3026.
https://doi.org/10.1182/blood.V130.Suppl_1.3026.3026
Published: 2017
Journal Articles

Circulating Cytokines and Markers of Iron Metabolism in Myelofibrosis Patients Treated with Momelotininb: Correlatives from the Ym-387-II Study

Vikas Gupta, MD FRCP, FRCPath, Ruben A. Mesa, Michael W Deininger, MD PhD, Candido E. Rivera, MD, Shireen Sirhan, MD FRCP, Srdan Verstovsek, MD, Yafeng Zhang, PhD, Yuanyuan Xiao, PhD, Helen Collins, MD, Kevin Kwei, Adarsh Joshi, PhD, Carrie Baker Brachmann, PhD
Journal: Blood
Blood (2015) 126 (23): 1600.
https://doi.org/10.1182/blood.V126.23.1600.1600
Published: 2015